Magazine Article | December 1, 2023

Finance And Funding: Anticipating Improvement, Planning For Uncertainty

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

This year’s predictions on the biopharma financing and funding environment are more optimistic than they were last year, with the persistent caveat of macroeconomic uncertainty, plus unresolved litigation on policy issues such as the Inflation Reduction Act. With deal activity increasing and the promise of novel product approvals in key therapeutic areas next year, however, small biotechs and (some) Big Pharmas appear poised to steer the industry into calmer waters. Business model creativity will become increasingly mandatory for companies marketing expensive products for small patient populations and larger population drugs in categories like obesity and CNS disorders.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader